Back to search results
NCT07307833

Impact of Immunotherapy on Vestibular Function, The Mayo Clinic Arizona Experience

Enrolling by Invitation
Not specifiedAges 18+Observational
Mayo Clinic
~50 participants
Updated 2026-06-16 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in clinically significant vestibulopathy - vestibular function
Measured over Baseline, 3 months, 6 months, 12 months
+2 more outcomes measured

Conditions

Hematopoietic and Lymphatic System Neoplasm
Malignant Solid Neoplasm

Explore related trials

Hematologic NeoplasmSolid Neoplasm

Where it's being run

1 sites across 1 states
Arizona1

Study leadership

  • Carrlene B. Donald, PA-C, MS · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

At least 18 years of age at screening
Patients who will be initiating single agent immunotherapy with pembrolizumab, cemiplimab, nivolumab, atezolizumab, or dual therapy with (Ipilimumab/Nivolumab or Nivolumab/Relatlimab)

Exclusion

Concurrent chemotherapy

What this trial measures

  • Change in clinically significant vestibulopathy - vestibular functionBaseline, 3 months, 6 months, 12 months

    Assessed using standard vestibular function testing. Results will be aggregated to determine overall vestibular function. Results from baseline (prior to initiating immunotherapy) will be compared to results at 3, 6, and 12 months.

  • Change in clinically significant vestibulopathy - hearing levelBaseline,12 months

    Assessed using Pure Tone Audiometry, a standard hearing test. Any change from baseline (prior to initiating immunotherapy) to 12 months will be reported.

  • Oscillopsia Severity Questionnaire (OSQ)Baseline, 3 months, 6 months, 12 months

    The OSQ consists of 9 questions to assess visual environment sensation (episodes of oscillopsia). Questions are answered on a 5-point scale: always, often, sometimes, seldom, never. The OSQ is scored by calculating a mean item score, which results in a total score ranging from 1 to 5. A score of 3 or higher indicates moderate to extreme oscillopsia severity.